Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).

In female patients assigned to mGPS category 1 or 2, a numerical trend towards longer OS was also observed in Arm A compared to Arm B, however, with statistical testing not revealing a significant survival difference between treatment arms (24.6 versus 16.7 months; P = 0.15) ( Supplementary Table S1 , available at https://doi.org/10.1016/j.esmoop.2024.103374 , Figure 4 A and B).

also in 337 other papers

In the present analysis, female patients showed a trend towards a benefit from less-intensive upfront chemotherapy, with this effect being more pronounced and almost reaching statistical significance in female patients with an mGPS of 0 (OS 41.6 months with fluoropyrimidine/bevacizumab alone versus 25.5 months with fluoropyrimidine/bevacizumab/irinotecan; P = 0.056) ( Supplementary Table S1 , available at https://doi.org/10.1016/j.esmoop.2024.103374 and Figure 4 A and B).

also in 18,965 other papers